Selective Pyroptosis in NF1-Deficient Cells through PKCδ Agonism.

Area of Science:

• Oncology
• Cell Biology
• Molecular Medicine

Background:

• Pyroptosis is an immunogenic cell death pathway with therapeutic potential, but selective induction is challenging.
• Loss of the NF1 tumor suppressor leads to hyperactivated RAS signaling, driving tumorigenesis in various cancers.
• NF1 deficiency creates a dependency on KRAS signaling, representing a potential therapeutic vulnerability.

Purpose of the Study:

• To investigate if PKCδ agonism can selectively induce pyroptosis in NF1-deficient cancer cells.
• To elucidate the molecular mechanisms by which PKCδ targets NF1-deficient cells.
• To evaluate the therapeutic efficacy of PKCδ agonism against NF1-deficient tumors.

Main Methods:

• Utilized cell culture models of NF1-deficient cancers.
• Employed biochemical assays to study protein phosphorylation and interactions (PKCδ, KRAS, caspase-8, BCL2).
• Administered PKCδ agonists to mouse models of NF1-deficient tumors for in vivo efficacy studies.

Main Results:

• PKCδ agonism selectively triggered pyroptosis in NF1-deficient cells.
• PKCδ phosphorylates KRAS, leading to KRAS-GDP accumulation and ER translocation.
• Phosphorylated KRAS-GDP promotes pyroptosis by activating caspase-8 and displacing BCL2.
• PKCδ agonism suppressed tumor growth in vivo for NF1-deficient neurofibroma and malignant peripheral nerve sheath tumors.

Conclusions:

• NF1-deficient cancers exhibit a unique vulnerability to PKCδ agonism via KRAS.
• The study identifies KRAS-GDP as a functionally active signaling molecule in this context.
• PKCδ agonism represents a promising, selective therapeutic strategy for NF1-deficient cancers.